Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies.
Recruiting
Observational Study
Lymphoma Neoplasms
Myeloma Multiple
Severe Infection
CMV Reactivation
Biespecific Treatment
Biespecific
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 350 (estimated)
- Sponsor
- Infanta Leonor University Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a prospective, multicenter, observational cohort study involving patients with hematologic malignancies who are receiving bispecific antibody therapy. The primary objective of this study is to evaluate the incidence, type, and severity of infectious complications in hematologic patients undergoing treatment with bispecific antibodies.
Secondary objectives include identifying risk factors …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Adult patients (≥18 years) diagnosed with hematologic malignancies (e.g., multiple myeloma, non-Hodgkin lymphoma) who are receiving treatment with bispecific antibodies.
2. Patients must have initiated BsAb therapy within 30 days prior to study enrollment.
3. Ability to provi…
Contacts